Jubilant Biosys Limited

Janssen Pharmaceutica Nv

Jubilant Episcribe LLC

Saravanan Vadivelu

Sridharan Rajagopal

Dhanalakshmi Sivanandhan

Chandrika Mulakala

Pavan Kumar Gondrala

Murugan Chinnapattu

Mark James Wall

Rajagopal Bakthavatchalam

Henricus Jacobus Maria Gijsen

Ishtiyaque Ahmad

Sivaramakrishna Battula

Christopher M Flores

Payal Kiran Parikh

Manjunatha M Ramaiah

Swapan Kumar Samanta

Manish Kumar Thakur

Tamizharasan Natarajan

Indu N Swamy

Nagendra Nagaraju

Subramaniam Kanagaraj

Zainuddin Mohd

Sayantani Sarkar

Hariprakash

Raghunadha Reddy Burri

Shivani Garapaty

Henricus Jacobus Gijsen

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like. 

Heterocyclic compounds as PRMT5 inhibitors

The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains. 

Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer

The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, an conditions mediated b one or more BET family of bromodomains.

Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors

Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R, R, R, and G are defined herein.

Substituted imidazoles as N-type calcium channel blockers

Growing community of inventors

Bengaluru, India

Saravanan Vadivelu